Xilio Therapeutics (XLO) Non Operating Income (2021 - 2026)
Xilio Therapeutics (XLO) posted Non Operating Income of $4.6 million for Q1 2026, down 79.35% sequentially from $22.2 million in Q4 2025, and up 682.08% YoY from $586000.0 in Q1 2025.
Xilio Therapeutics (XLO) Non Operating Income (2021 - 2026) Analysis & Trends
Xilio Therapeutics has reported Non Operating Income for 6 years, with the latest figure at $4.6 million in Q1 2026.
- Quarterly Non Operating Income rose 682.08% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 314.04% YoY) and the FY2025 annual result came in at $6.9 million, up 196.71% from the prior year.
- Non Operating Income fell to $4.6 million in Q1 2026 per XLO's latest filing, from $22.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $22.2 million in Q4 2025 and troughed at -$14.4 million in Q3 2025.
- A 5-year average of $1.0 million and a median of $586000.0 in 2025 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 4041.04% in 2025, down 2035.04% in 2025.
- Over 5 years, Non Operating Income stood at $701000.0 in 2022, then slumped by 32.24% to $475000.0 in 2023, then increased by 12.84% to $536000.0 in 2024, then surged by 4041.04% to $22.2 million in 2025, then tumbled by 79.35% to $4.6 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $4.6 million, $22.2 million, and -$14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.88 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Dec 31, 2025 | 22.20 Mn |
| Sep 30, 2025 | -14.36 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 536,000.00 |
| Sep 30, 2024 | 742,000.00 |
| Jun 30, 2024 | 779,000.00 |
| Mar 31, 2024 | 284,000.00 |
| Dec 31, 2023 | 475,000.00 |
| Sep 30, 2023 | 613,000.00 |
| Jun 30, 2023 | 761,000.00 |
| Mar 31, 2023 | 880,000.00 |
| Dec 31, 2022 | 701,000.00 |
| Sep 30, 2022 | 416,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | -129,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | -290,000.00 |